This information was published on 2024-04-04T04:29:53 for IP Right Filed Published.
| Field | Value |
| (210) | 2440413 (IR 1783466) |
| (220) |
26 Jan 2024
|
| (300) |
US, 08 Aug 2023, 98122765
|
| (511) (510) |
Class 5
Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for providing stem cell therapy; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use; pharmaceutical preparations for use in oncology. Class 42 Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy; development of therapeutics and cell therapies; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology. Class 44 Cancer treatment medical services; oncolytic virotherapy medical services; stem cell therapy services; medical services in the field of oncology; medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor T-cells for use in treating disease, namely, the treatment of cancer. |
| (540) | VYRIAD |
| (550) | Word |
| (730) |
Vyriad, Inc.
|
Find out more about publications on the About page.